"C0040233"^^ . "BlocadrenSYNCI" . "91524-16-2"^^ . "BetimolBRNCI" . . "TIMOLOLPTFDA817W3C6175" . "TimololPTDCP30216" . . "CHEBI:60787"^^ . "TimololPTNCI" . . "Timolol"^^ . "2C13H24N4O3S.H2O"^^ . . . "(S)-1-(tert-Butylamino)-3-((4-morpholino-1,2,5-thiadiazol-3-yl)oxy)propan-2-olSNNCI" . "Timolol"^^ . "Timolol"^^ . "817W3C6175"^^ . "C47757"^^ . "2-Propanol, 1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-, hemihydrate, (S)-SNNCI" . "Pharmacologic Substance"^^ . "A propanolamine derivative and a non-selective beta-adrenergic antagonist with antihypertensive property. Timolol competitively binds to beta-1-adrenergic receptors in the heart and vascular smooth muscle and beta-2-receptors in the bronchial and vascular smooth muscle, resulting in a decrease in beta-adrenergic stimulation. Beta-1-receptor blockade results in a decrease in resting and exercise heart rate and cardiac output, a decrease in both systolic and diastolic blood pressure, and, possibly, a reduction in reflex orthostatic hypotension. Beta-2-blockade results in an increase in peripheral vascular resistance. The ultimate results include vasodilation, and negative chronotropic and inotropic cardiac effects. In addition, timolol reduces intra-ocular pressure possibly by decreasing aqueous humor production by reduction of blood flow to the ciliary processes and cAMP synthesis.NCI" . "FDA"^^ . . .